OBJECTIVES: Cardiopulmonary bypass (CPB) is an essential component of many cardiac interventions, and therefore, there is an increasing critical demand to minimize organ damage resulting from prolonged extracorporeal circulation. Our goal was to develop the first clinically relevant mouse model of CPB and to examine the course of extracorporeal circulation by closely monitoring haemodynamic and oxygenation parameters.
INTRODUCTION
Cardiopulmonary bypass (CPB) is an essential component of conventional cardiac surgery. Because of an increasing number of successfully performed combined cardiac surgical procedures, the average time of CPB is constantly being prolonged. For example, to perform sophisticated surgical procedures such as multiple valve replacement combined with coronary artery bypass grafting or aortic repair, surgeons require significantly extended heart-lung machine and cardioplegia time. During the last few decades, clinical protocols have had significant improvements in terms of cardiac protection as well as reducing the levels of systemic damage induced by prolonged CPB time [1, 2] . Nevertheless, there is an increasing critical demand to further reduce systemic inflammatory response syndrome and acute organ injury associated with CPB.
To date, CPB has been modelled in sheep, pigs, dogs, rabbits and rats [3, 4] . Animal models of CPB are essential to investigate the effects of CPB in relation to different insults (e.g. hypoperfusion, hyperthermia and cerebral emboli) and comorbidities (e.g. diabetes mellitus, atherosclerosis and hypertension). Moreover, animal models facilitate preclinical testing of new neuro-and cardioprotective drugs. Large animal models have the obvious disadvantages of being costly and challenging to genetically manipulate. The rat model of CPB has been significantly improved over the years and has provided important information regarding diverse organ injuries [5] [6] [7] [8] [9] . A mouse model of CPB would have many advantages over other animal models in that mice are inexpensive, easy to handle and one can benefit from the availability of genetically modified mice and mouse-specific reagents. Moreover, there are a plethora of mice strains available suffering from diverse clinically relevant diseases including cardiomyopathy, coronary diseases, aortic aneurysm, cystic fibrosis, diabetes mellitus and pulmonary hypertension [10, 11] . Accordingly, we †The last two authors contributed equally to this work. set out to develop a clinically relevant model of CPB in mice that could be used to investigate CPB in relation to various insults and comorbidities as well to dissect the underling molecular mechanisms involved in systemic inflammatory response syndrome and acute organ injury.
Here, we report the establishment of the first fully functioning model of CPB in mice. We describe the device design, perfusion circuit and microsurgical techniques as well as validate physiological function during the procedure. Because of multiple blood samplings needed to test stable haemodynamic and oxygenation parameters during CPB, this novel model was designed as an acute experiment and not as a survival model.
METHODS

Animals
Nine male Mus musculus Naval Medical Research Institute mice were obtained from Charles River. Mice weighing between 25 g and 35 g were used for CPB. All animal experiments were performed in compliance with the German Animal Protection Law (TierSchG) and were approved by the local animal welfare committee (Lower Saxony State Office for Consumer Protection and Food Safety, Protocol TSA 14/1556).
Anaesthesia
Animals were anaesthetized with isoflurane in an induction chamber, orotracheally intubated and mechanically ventilated using an isoflurane vaporizer connected to a mouse ventilator (Harvard Apparatus Inc., Holliston, MA, USA). The concentration of isoflurane anaesthetic was maintained between 1.3% and 2.5% in oxygen depending on the stage of the procedure, with a constant flow rate of 0.5 l/min. The tidal volume for ventilation was 250-350 ml depending on the weight of the animal. Additional analgesia was given by subcutaneous injection of carprofen (Zoetis, Parsippany, NJ, USA) at a dose of 5 mg/kg body weight.
Heart-lung machine construction
To provide sufficient blood circulation for animals weighing 25-35 g, a CPB circuit ( Fig. 1 ) with a priming volume of 850 ml was adapted and optimized with respect to the peristaltic pump, micro-cannulation tubing, and micro-oxygenator. A customized low-flow peristaltic pump ( Fig. 2A ; P-1, GE Healthcare Europe, Buc, France) provided a flow rate between 0.5 ml/min and 8.0 ml/min. The driving electronics of the roller pump are adjusted to increase the rotation speed to allow sufficient flow within small diameter tubes. For microcannulation, 1-and 2-Fr polyurethane catheters (Instech Laboratories, Inc., Plymouth Meeting, PA, USA) were used in combination with silicone capillary tubes having an internal diameter of 0.5 mm (ESSKA Maschinen Vertriebs GmbH, Hamburg, Germany). The self-built micro-oxygenator (Fig. 2B ) had a 300-ml chamber containing fifty 80-mm long polypropylene hollow fibres able to provide an oxygen/air mixture with 80% fraction of inspired oxygen at a rate of 1 l/min. The air-trapping chamber consisted of a 300-ml chamber with 1 outflow and 2 inflow microconnectors.
Physiological monitoring
Electrocardiography, rectal temperature and invasive blood pressure were monitored using a multichannel PowerLab data acquisition device (ADInstruments Ltd, Dunedin, Otago, New Zealand). Additionally, routine blood gas analyses (BGAs; ABL 800 Flex, Radiometer, Brønshøj, Denmark) were conducted by sampling 95 ml of venous or arterial blood at fixed time points during CPB.
Surgical procedure and cannulation
After orotracheal intubation, the CPB circuit was primed with 850 ml of a 3:1 solution of Tetraspan:Sterofundin (B Braun Medical, Melsungen, Hesse, Germany) that had been heparinized with 30 IU/ml of perfusion solution and buffered with 2.5% v/v of an 8.4% solution of sodium bicarbonate. A midline skin incision was made on the neck, and the right jugular vein and left carotid artery were exposed using sharp and blunt preparation (Fig. 2C) . The distal segment of the left common carotid artery was ligated prior to bifurcation, and slip knots were placed at the proximal segment of the artery. The tip of a 27-G intravenous cannula was connected to the arterial inflow tubing, inserted into the carotid artery and moved 5 mm proximally towards the aortic arch. Subsequently, the right jugular vein was exposed and animals were heparinized (2.5 IU/g body weight) via direct intravenous injection. For cannulation of the right jugular vein, a 2-Fr polyurethane tube was perforated before the operation with a surgical blade and microscissors under a microscope. In total, 4 fenestrations were made within the distal third of the cannulae. The cannula was then inserted into the jugular vein and moved towards the right atrium into the right ventricle or inferior vena cava. From experience, we determined that the venous cannula should be placed 2.5 cm distally to the clavicle to allow adequate and reliable backflow from the venous system. For real-time invasive pressure monitoring, as well as arterial blood sampling, the left femoral artery was cannulated with a 1-Fr polyurethane cannula and connected to a Powerlab transducer. Lastly, a small 5-mm long upper sternotomy incision was made, and the aortic arch was exposed by pulling the right carotid artery in the cranial direction and by placing a loop (8-0 silk) around the ascending aorta (Fig. 2D) . Consequently, the ascending aorta could be pulled cranially to facilitate clamping for cardioplegia.
Cardiopulmonary bypass
CPB was initiated slowly with a flow rate of 0.5 ml/min and was increased within 2 min to full flow ranging from 4 ml/min to 6 ml/ min, based on systemic pressure measurements. Afterwards, respiratory arrest (RA) was initiated and maintained for 60 min. To achieve mild hypothermia, the mouse's body temperature was cooled in the first 20 min of RA to 28 C. After 30 min of RA, cardioplegia was performed by giving 0.3 ml of 7.45% potassium chloride solution into the CPB circuit and by placing a micro-serrefine clamp on the ascending aorta. After 60 min of RA and 30 min of cardiac arrest, the mouse was reventilated and warmed to 37 C. At the same time, the micro-serrefine clamp was removed from the ascending aorta and heart reperfusion was initiated. Arterial and venous blood samples were taken for BGA after (i) 10 min of CPB plus ventilation (BGA 1); (ii) 25 min of CPB, 15 min of RA (BGA 2); (iii) 40 min of CPB, 30 min RA (BGA 3) and after (iv) 55 min CPB, 45 min RA, 15 min cardiac arrest (BGA 4) (Fig. 3 ). After CPB was terminated, physiological measurements were monitored for another 20 min. At the end of the experiment, animals were euthanized by exsanguination under ongoing cardiac arrest and full isoflurane anaesthesia. Blood and organs were retrieved for further analysis.
Clinical chemistry
Clinical chemistry tests to assess renal and hepatic functions were performed on an AU 400 Olympus analyser (Olympus, Tokyo, Japan) according to the manufacturer's instruction. For renal function, serum creatinine and blood urea nitrogen were measured, and for liver function, alanine transaminase and aspartate transaminase were measured.
Histopathology
Kidney, lung, liver and heart samples were obtained from all 9 mice. Tissue was fixed in 4% paraformaldehyde, stored for 24 h at 4 C and then embedded in paraffin. Periodic acid-Schiff staining was performed using 4-mm-thick sections to assess renal and liver morphology.
Statistics
Statistical analyses were performed on clinical chemistry results using GraphPad Prism 5 software (San Diego, CA, USA). MannWhitney tests for non-parametric data were performed. A P-value of < _0.05 was considered significant.
RESULTS
In total, 9 mice underwent CPB. Because of technical difficulties due to the small volume of arterial blood sampled, BGA data were not available for every mouse at every time point tested. Accordingly, the number of data points per time point differs.
Perfusion and haemodilution
Mean arterial pressure measured in all mice was kept between 40 mmHg and 55 mmHg. Minimal and maximal extracorporeal membrane oxygenation flow was 2.3 and 6.5 ml/min, respectively, depending on the animal's weight, body temperature and volume substitution. During the course of an experiment, an average of 0.1 ml of priming solution was given approximately every 20 min to maintain proper venous outflow due to gradual loss of the intravasal volume. To maintain a stable pH, 8.4 mmol/l sodium hydrogen carbonite solution was added to the airtrapping reservoir.
The total priming volume was low. To sustain perfusion pressure and sufficient venous backflow, up to 0.6 ml of extra priming solution was given to mice resulting in haemodilution. Any blood that leaked from open wounds was collected and returned to CPB circuit through the air-trapping reservoir. However, over the course of all experiments, haemoglobin levels could be maintained at sufficient levels, without the need for blood transfusion (Fig. 4A) .
Haematocrit levels at the beginning of CPB ranged from 0.21 and 0.27 (Fig. 4B, BGA 1 ) and fell gradually to 0.19 ± 0.01 at the end of CPB (Fig. 4B, BGA 4) .
Oxygenation
Arterial partial pressure of oxygen (pO 2 ) obtained from the femoral artery at fixed time points showed excellent oxygenation in BGA (Fig. 5A) . After 10 min of CPB and ventilation (BGA 1), arterial pO 2 ranged from 135 to 590 mmHg. After 15 min of RA, the minimal level of pO 2 was 81.8 mmHg and the maximal level was 506 mmHg (BGA 2). Subsequently, pO 2 increased, which was directly related to lower oxygen consumption in the hypothermic state (BGAs 3 and 4) . Despite sufficient arterial oxygenation, one animal developed hypercapnia with partial pressure of carbon dioxide values between 60 and 80 mmHg due to lung oedema and consequent capillary leak in the bronchial system (Fig. 5B) . In general, however, good expiration of carbon dioxide through the micro-oxygenator could be achieved in most animals provided an oxygen/air mixture at 80% fraction of inspired oxygen.
Oxygen saturation in the arterial blood was sufficient, ranging from 0.75 to 1 over the course of the experiment (Fig. 5C ). In the initial phases of RA (Fig. 5C , BGAs 2 and 3), arterial oxygen saturation was at its lowest, but under mild hypothermia, levels increased by 60 min of RA (BGA 4).
pH and lactate
After starting CPB, a slight shift in the blood gases to respiratory alkalosis was observed in some animals with the pH ranging from 7.3 to 7.6 before the initiation of RA (Fig. 6A, BGA 1) . During RA, pH tended to gradually reduce, averaging 7.16 ± 0.2 after 15 min (BGA 2). Continuous buffering of the animal allowed the pH to be maintained above 7.24 ± 0.32 until the end of CPB, thus preventing severe acidosis.
At the start of CPB, lactate levels were variable (range of 1.9-6.3 mmol/l) with an average value of 3.8 ± 1.6 mmol/l (Fig. 6B , BGA 1). After 15 (BGA 2) and 30 min (BGA 3) of RA, lactate levels rose, however, buffering with bicarbonate-reduced lactate levels after 45 min of RA (BGA 4).
During CPB, despite correction of acidosis with bicarbonate, HCO 3 -deficit (Fig. 6C ) and negative base excess parameters (Fig.  6D) were observed showing non-progressive acidosis within 80 min of CPB. Over the course of the procedure, HCO 3 -levels fell and base excess parameters were negative and highly variable in all animals.
Biochemical and histopathological assessment of organ damage after circulatory arrest and reperfusion
Twenty minutes after CPB was terminated, serum creatinine, blood urea nitrogen, alanine transaminase and aspartate transaminase were not significantly different compared with 10 min of CPB plus ventilation (BGA 1) (Fig. 7A-D) . At this time point, kidney, liver, heart and lung tissues from all 9 mice were examined for signs of organ damage. In the kidney, there were focal areas that displayed early signs of acute kidney injury characterized by distended tubular lumens (Fig. 7E) . Upon periodic acid-Schiff staining, intracellular glycogen storage in hepatocytes appears violet and liver damage is characterized by the loss of glycogen storage ability and therefore a pale appearance. Twenty minutes after termination of CPB, mice showed early signs of liver injury with certain areas displaying a loss of glycogen storage capacity (Fig. 7E) . In the lung, focal and multifocal atelectases were observed, whereas there were no signs of oedema, vascular damage or injury to the respiratory epithelium (Fig. 7E) . The heart showed mild perivascular oedema, but no indication of acute inflammation, bleeding or necrosis (Fig. 7E) .
DISCUSSION
Animal models of CPB are useful to study the effects of different insults (e.g. cerebral embolism, hypofusion and hyperthermia), complications (e.g. cardiac insufficiency, neurological/cognitive impairment and excessive immune activation) and to test cardioprotective measures. We have established the first ever murine model of CPB, which has significant advantages over other animal models. Recently, Luo et al. [12] reported a novel mouse model of extracorporeal circulation, confirming the feasibility of such a model for future research regarding extracorporeal circulation-induced systemic inflammatory response and organ injury. In Luo et al.'s model, however, no oxygenator was included in the CPB circuit. Therefore, our model is a significant step forward, with complete CPB including an entire heart-lung machine system and oxygenator. Development of our model involved extensive testing, trials and preliminary versions to optimize the pump, tubing, oxygenator, reservoir system, air trap and cannulation technique for mice. Here, we discuss the technical innovations that facilitated adaptation and optimization of CPB for use in mice.
A primary challenge was to reduce the priming volume of the overall system. At the beginning of the development, the priming volume in the whole system was 6 ml. Initial attempts at reducing tubing size resulted in intrasystemic (intratubing) pressure exceeding 700 mmHg, thereby resulting in leakage. Adjustment of rotation speed resulted in a stable circulatory system having moderate intrasystem pressure (<500 mmHg) and a maximal flow rate of 9 ml/min. In this way, priming volume in the whole system was reduced to <0.9 ml without the venous reservoir.
The smallest micro-oxygenator reported required a priming volume of 1.2 ml to maintain necessary blood gases in vitro. In hollow fibre oxygenators, gas exchange is achieved as oxygen flows through, and blood flows around tightly packed hollow fibres. This provides maximum exchange of carbon dioxide and oxygen over a large surface area. The primary disadvantage of such oxygenators is the priming volume of >1 ml, which represents 50% of the total blood volume of a mouse. We discovered that sufficient gas exchange could be achieved when an inverted model of gas-liquid interaction was employed. Some clinical oxygenators also use this configuration.
We minimized the oxygenator's priming volume by engineering a small chamber, where blood was perfused through 50 hollow fibres (Figs 1 and 2) . The oxygen-air mixture was supplied between parallelly adjusted hollow fibres. With these improvements, we achieved maximal gas exchange with excellent blood gas values while minimizing the priming volume of the oxygenator to <0.3 ml. Importantly, these adjustments did not lead to increases in systemic pressure or intratubing resistance.
A common technical challenge in maintaining CPB is the gradual loss of intravascular volume to the interstitium that results in a loss of peripheral resistance. However, using hyperosmolar solutions, this issue was minimized during our experiments. One issue that arises in the rat model of CPB is the occurrence of arterial air embolisms caused by aspiration of air bubbles into the venous tubing. CPB in patients is supplied by an air filtering system; however, these have high flow resistance and could therefore not be used in miniature pumps. To avoid air embolisms, our circuit did not have a venous reservoir, and so we designed an additional air-trapping reservoir between the oxygenator and arterial cannula.
HCO 3 -deficit and negative base excess parameters were observed and could be explained by improper buffering with bicarbonate in extremely small volumes. Controlled injection of bicarbonate using an infusion pump system might avoid this problem and will be tested in future experiments.
Clinical chemistry indicators 20 min after CPB termination showed only slight indications of kidney and liver dysfunction. Histological assessment of the liver and kidney at the same time point revealed the beginnings of acute organ injury. Since kidney and liver dysfunction are well-known clinical complications after CPB, this model offers the opportunity to study mechanisms of acute organ injury and preventive treatment strategies, particularly when the model can be adapted to a survival model. Heart and lung tissue alternations 20 min after CPB termination were mild, which contrasts several large animal studies [13, 14] but is encouraging for a future survival model. Our mouse model of CPB demonstrated sufficient and clinically relevant haemodynamic and oxygenation parameters. It was an acute, nonsurvival experiment as multiple blood samplings (up to 0.9 ml in total) made it incompatible with survival. In practice, a maximum of 200 ml of blood could be taken from a living healthy animal at least 1 week before any intervention starts. We are now establishing a survival model (24-h observation time), where blood sampling is limited to 200 ml to prevent the necessity of blood transfusions. In addition, we are continuing to further reduce the priming volume that will significantly improve outcomes. In a future survival model, it will be interesting to study inflammation and tissue responses after CPB.
CONCLUSION
In conclusion, we have developed a novel mouse model of CPB with the smallest priming volume reported to date in the literature. Despite technical problems in metabolic correction, our acute experimental model provides stable and reproducible haemodynamic and respiratory parameters comparable to data from rat CPB reports. Together with the plethora of genetically modified mice available, our mouse CPB model will allow investigation of the molecular mechanisms involved in acute organ injury and facilitate the study of CPB in the context of various comorbidities. Numerous murine models with relevant cardiovascular defects (e.g. cardiomyopathy, tachycardia and bradycardia) or diseases (e.g. atherosclerosis, diabetes mellitus, hypocholesterolaemia and hypertension) are readily available. For our next experiments, we will be performing prolonged cardioplegia with extended CPB time in a mouse model of cardiomyopathy [FVB/N-Tg (Myh6 -Gnaq) 40 Gwd/J mice] to test putative cardioprotective drugs that may improve myocardial ischaemic injury. Our aim is to compensate low cardiac output syndrome observed after longer post-surgical heart ischaemia in the clinic. Despite 99% of human genes being conserved in mice, we recognize that not all aspects of human disease can be accurately modelled in mice. However, mouse models offer too many advantages to overlook the profound impact they can have on understanding human disease. In this respect, humanized mouse model may help to bridge the gap between animals and humans in preclinical research. In addition, the techniques described in our CPB model may foster novel microsurgical protocols in mice such as orthotopic thoracic organ transplantation as well as aortic and valve surgery.
